Lenalidomide clinical trials
Also written Revlimid, CC-5013 and CDC 501.
How each study uses Lenalidomide is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Lenalidomide studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 27 Dec 2005 · REVLIMID · NDA 021880 (FDA, Drugs@FDA)
- European Union
- 14 Jun 2007 · Revlimid · EMEA/H/C/000717 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
749 studies that test it; most in 2009 (68); 2 more planned to start later
| Year | Studies |
|---|---|
| 2002 | 8 |
| 2003 | 8 |
| 2004 | 16 |
| 2005 | 29 |
| 2006 | 23 |
| 2007 | 30 |
| 2008 | 54 |
| 2009 | 68 |
| 2010 | 63 |
| 2011 | 40 |
| 2012 | 47 |
| 2013 | 28 |
| 2014 | 25 |
| 2015 | 26 |
| 2016 | 30 |
| 2017 | 25 |
| 2018 | 21 |
| 2019 | 29 |
| 2020 | 36 |
| 2021 | 23 |
| 2022 | 36 |
| 2023 | 20 |
| 2024 | 27 |
| 2025 | 23 |
| 2026 | 14 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 108 · Other 643
M.D. Anderson Cancer Center (46) · Celgene (43) · National Cancer Institute (NCI) (42) · Mayo Clinic (24) · Celgene Corporation (23) · Memorial Sloan Kettering Cancer Center (19) · Dana-Farber Cancer Institute (12) · H. Lee Moffitt Cancer Center and Research Institute (12)
Often tested with
Tested in the same studies.
Dexamethasone (170) · Rituximab (95) · Bortezomib (57) · Daratumumab (36) · Cyclophosphamide (29) · Carfilzomib (25) · Obinutuzumab (21) · Azacitidine (21)
Related medicines
As reviewed, each with the page that says it.
- One of Immunologic Factors source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 12 phase 3 studies under way
Lenalidomide is the comparator. A study of two new drugs counts under both.
- 2Ramantamig · Janssen Research & Development, LLC · next primary completion Sep 2030
- 1Zanubrutinib · BeOne Medicines · next primary completion Jul 2028
- 1Rituximab · BeOne Medicines · next primary completion Jul 2028
- 1Iberdomide · Bristol-Myers Squibb · next primary completion Mar 2029
- 1Elranatamab · Pfizer · next primary completion Aug 2027
- 1Axicabtagene ciloleucel · Kite, A Gilead Company · next primary completion Oct 2030
- 1Anti-CD19/CD3 Bispecific Antibody MK-1045 · Merck Sharp & Dohme LLC · next primary completion Mar 2037
- 1Bcl-2 Inhibitor TQB3909 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · next primary completion Dec 2030
Reaching primary completion within a year · 43, 5 in phase 3
Studies that test Lenalidomide, phase 3 first.
- Dec 2026Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple MyelomaPhase 3 · ECOG-ACRIN Cancer Research Group
- Feb 2027A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.Phase 3 · Epizyme, Inc.
- Aug 2027Expression-linked and R-ISS-adapted Stratification for First Line Therapy in Multiple Myeloma PatientsPhase 2/3 · University Hopsital Schleswig Holstein Campus Lübeck
- Sep 2027Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone LymphomaPhase 3 · The Lymphoma Academic Research Organisation
- Nov 2027Trial of Carfilzomib, Lenalidomide, Dexamethasone Versus Lenalidomide Alone After Stem-cell Transplant for Multiple MyelomaPhase 3 · University of Chicago
- Nov 2026Study of Lenalidomide, Venetoclax and Obinutuzumab in Patients With Treatment-Naïve Follicular LymphomaPhase 1/2 · Peter MacCallum Cancer Centre, Australia
- Dec 2026Immunotherapy of Relapsed Refractory Neuroblastoma With Expanded NK CellsPhase 1 · New Approaches to Neuroblastoma Therapy Consortium
- Dec 2026Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MMPhase 2 · Alliance Foundation Trials, LLC.
- Dec 2026Zanubrutinib, Obinutuzumab and Lenalidomide (ZGR) in High-risk Treatment-naive Patients with Follicular Lymphoma (FL)Phase 2 · Ruijin Hospital
- Dec 2026A Study to Assess Safety and Efficacy of CHO-H01 as a Single Agent/Combined With Lenalidomide in Subjects With Refractory or Relapsed Non-Hodgkin's LymphomaPhase 1/2 · Cho Pharma Inc.
Studies
Open first, then newest update. How each study uses Lenalidomide is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 751
- Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)RecruitingPhase 1National Cancer Institute (NCI)NCT04301076Written as Lenalidomide
- Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell LymphomaRecruitingPhase 1/2National Cancer Institute (NCI)NCT03223610Written as Revlimid (lenalidomide)
- Zanubrutinib Plus Lenalidomide for Frail Elderly Patients With Newly Diagnosed PCNSLRecruitingPhase 2Xiaohui RenNCT07839247Written as Lenalidomide
- Lenalidomide and Cosibelimab for the Treatment of Relapsed/Refractory Mycosis Fungoides or Sézary SyndromeNot yet recruitingPhase 1City of Hope Medical CenterNCT07926893Written as Lenalidomide
- Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell LymphomaRecruitingPhase 2National Cancer Institute (NCI)NCT06649812Written as Lenalidomide
- Prophylactic Strategies for Mitigating Central Nervous System Relapse in Diffuse Large B-Cell LymphomaNot yet recruitingPhase 2Cancer Institute and Hospital, Chinese Academy of Medical SciencesNCT07917624Written as Lenalidomide
- Zilovertamab Vedotin and Lenalidomide (ZiVLen) Therapy for Relapsed/Refractory Peripheral T-Cell LymphomaNot yet recruitingPhase 2Olivia Newton-John Cancer Research InstituteNCT07913594Written as Lenalidomide
- Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple MyelomaRecruitingPhase 2M.D. Anderson Cancer CenterNCT05091372Written as Lenalidomide
- Acalabrutinib, Lenalidomide, and Rituximab for the Treatment of CD20 Positive Stage III-IV, Grade 1-3a Follicular LymphomaRecruitingPhase 2M.D. Anderson Cancer CenterNCT04404088Written as Lenalidomide
- Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell LymphomaRecruitingPhase 1National Cancer Institute (NCI)NCT06015880Written as Lenalidomide
- Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell LymphomaRecruitingPhase 1/2City of Hope Medical CenterNCT05861050Written as Lenalidomide
- Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple MyelomaRecruitingPhase 1/2Wake Forest University Health SciencesNCT04822337Written as Carfilzomib, Lenalidomide, Dexamethasone, Belantamab Mafodotin
- Post-Transplant Maintenance Therapy With Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma PatientsRecruitingPhase 2M.D. Anderson Cancer CenterNCT05776979Written as lenalidomide
- Chidamide, Lenalidomide, and Rituximab in Newly Diagnosed Elderly/unFit DE-DLBCLRecruitingPhase 2The First Affiliated Hospital with Nanjing Medical UniversityNCT07884708Written as Chidamide in combination with Lenalidomide and Rituximab (CR2)
- A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in CombinationsRecruitingPhase 1/2AbbVieNCT06892522Written as Lenalidomide
- A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for TransplantRecruitingPhase 2/3AbbVieNCT07095452Written as Lenalidomide
- Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell LymphomaRecruitingPhase 1/2City of Hope Medical CenterNCT03523975Written as Lenalidomide
- Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM PatientsRecruitingPhase 3Intergroupe Francophone du MyelomeNCT06918002Written as Lenalidomide (Revlimid®)
- Response-adaptive to Epcoritamab In First Relapse: Study to Evaluate the Efficacy of Eptoritamab in Patients With Relapse/Refractory Large B Cell LymphomaRecruitingPhase 2Grupo Español de Linfomas y Transplante Autólogo de Médula ÓseaNCT07126236Written as Epcoritamab, tafasitamab and lenalidomide
- ERd Combination Treatment in Newly Diagnosed Multiple Myeloma (ADVANCE 2.0)RecruitingPhase 2University of MiamiNCT06997081Written as Lenalidomide
See all 751 studies that test Lenalidomide →
Given beside what is tested · 264 — Lenalidomide is usual care or a partner of the new treatment
- A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone LymphomaRecruitingPhase 3Regeneron PharmaceuticalsNCT06149286Written as Lenalidomide
- Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple MyelomaRecruitingPhase 3PrECOG, LLC.NCT07285239Written as Lenalidomide
- A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple MyelomaRecruitingPhase 1/2Hoffmann-La RocheNCT05583617Written as Lenalidomide
- A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care TreatmentsRecruitingPhase 1Regeneron PharmaceuticalsNCT05137054Written as Lenalidomide
- A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple MyelomaRecruitingPhase 3Janssen Research & Development, LLCNCT05552222Written as Lenalidomide
- A Study of JNJ-95566692 in Participants With Non-Hodgkin Lymphoid MalignanciesRecruitingPhase 1Janssen Research & Development, LLCNCT07308132Written as Lenalidomide
- Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null PhenotypeRecruitingPhase 1Andrew Hantel, MDNCT07341867Written as LENALIDOMIDE
- To Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Autologous Stem Cell Transplant in Newly Diagnosed Multiple MyelomaNot yet recruitingPhase 3Kite, A Gilead CompanyNCT07903506Written as Lenalidomide
- Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to TreatmentRecruitingPhase 2SWOG Cancer Research NetworkNCT05890352Written as Lenalidomide
- A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for TransplantRecruitingPhase 3PfizerNCT05623020Written as Lenalidomide
- Less Doses of Daratumumab Are Adequate to Achieve Response in Newly Diagnosed Multiple MyelomaRecruitingPhase 2Tata Memorial CentreNCT07891923Written as Len (lenalidomide)
- CM336 Plus Daratumumab and Lenalidomide in Transplant-Ineligible Newly Diagnosed Multiple MyelomaNot yet recruitingPhase 2Institute of Hematology & Blood Diseases Hospital, ChinaNCT07830485Written as Lenalidomide
- Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM TrialRecruitingPhase 2National Cancer Institute (NCI)NCT07605416Written as Lenalidomide
- Comparing Bispecific Antibody Treatment to Autologous Stem Cell Transplant for Newly Diagnosed, Standard Risk Multiple MyelomaNot yet recruitingPhase 2/3Alliance for Clinical Trials in OncologyNCT07887984Written as Lenalidomide
- A Trial to Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Standard of Care in Newly Diagnosed Multiple MyelomaNot yet recruitingPhase 3Kite, A Gilead CompanyNCT07887672Written as Lenalidomide
- A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).RecruitingPhase 3AstraZenecaNCT07735637Written as Lenalidomide
- International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From IsatuximabEnrolling by invitationPhase 2SanofiNCT05669989Written as Lenalidomide
- Fixed Duration vs Continuous Anti-CD38 Antibody Therapy Among Transplant Ineligible Older Adults With Newly-Diagnosed Multiple MyelomaRecruitingPhase 3Canadian Cancer Trials GroupNCT06182774Written as Lenalidomide
- A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple MyelomaRecruitingPhase 1Janssen Research & Development, LLCNCT06768489Written as Lenalidomide
- Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell LymphomaRecruitingPhase 3Stichting Hemato-Oncologie voor Volwassenen NederlandNCT06220032Written as Lenalidomide
Showing 20 of 264.
As the comparator · 22 — what is tested is compared with Lenalidomide
- A Clinical Trial of MK-1045 With Zilovertamab Vedotin in Participants With Diffuse Large B-cell Lymphoma (MK-1045-010)Not yet recruitingPhase 2/3Merck Sharp & Dohme LLCNCT07917754Written as Lenalidomide
- A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell LymphomaRecruitingPhase 3Hoffmann-La RocheNCT06084936Written as Lenalidomide
- A Trial Comparing Ramantamig and Daratumumab (Ramantamig-D) Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant EligibleNot yet recruitingPhase 3Janssen Research & Development, LLCNCT07903272Written as Lenalidomide
- A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not PlannedRecruitingPhase 3Janssen Research & Development, LLCNCT07665450Written as Lenalidomide
- A Open-Label Phase in Participants With Multiple MyelomaNot yet recruitingPhase 2Innovent Biologics (Suzhou) Co. Ltd.NCT07764861Written as Lenalidomide
- A Clinical Trial to Evaluate the Efficacy and Safety of TQB3909 Tablets Versus Investigator's Choice in the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)Not yet recruitingPhase 3Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT07753369Written as Lenalidomide Capsules
- A Study Comparing Treatment With Teclistamab and Talquetamab Versus Daratumumab and Lenalidomide in Patients With Multiple Myeloma After Stem Cell Transplant Who Still Have Detectable DiseaseNot yet recruitingPhase 3Polish Myeloma ConsortiumNCT07740486Written as Lenalidomide
- Immuno-PRISM (PRecision Intervention Smoldering Myeloma)RecruitingPhase 2Irene Ghobrial, MDNCT05469893Written as Lenalidomide
- HDM2005 Combination Therapy in Relapsed/Refractory Mantle Cell LymphomaNot yet recruitingPhase 1Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.NCT07697339Written as Rituximab plus lenalidomide
- A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)RecruitingPhase 3CelgeneNCT06911502Written as Lenalidomide
- Isa-VRD in TIE HRMMNot yet recruitingPhase 4Peking Union Medical College HospitalNCT07334535Written as Bortezomib, Lenalidomide, Dexamethasone
- A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell LymphomaRecruitingPhase 2Guangzhou Lupeng Pharmaceutical Company LTD.NCT07189065Written as Lenalidomide
- Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone LymphomaRecruitingPhase 3Beijing InnoCare Pharma Tech Co., Ltd.NCT06082102Written as Lenalidomide
- A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone LymphomaActive, not recruitingPhase 3BeOne MedicinesNCT05100862Written as Lenalidomide
- Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple MyelomaActive, not recruitingPhase 2National Cancer Institute (NCI)NCT06169215Written as Lenalidomide
- A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple MyelomaActive, not recruitingPhase 3Bristol-Myers SquibbNCT05827016Written as Lenalidomide
- Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After TransplantActive, not recruitingPhase 3PfizerNCT05317416Written as Lenalidomide
- A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular LymphomaWithdrawnPhase 3Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyNCT06313996Written as Lenalidomide
- Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular LymphomaActive, not recruitingPhase 3Kite, A Gilead CompanyNCT05371093Written as Lenalidomide
- Study of Dexamethasone Plus IXAZOMIB (MLN9708) or Physicians Choice of Treatment in Relapsed or Refractory Systemic Light Chain (AL) AmyloidosisTerminatedPhase 3Millennium Pharmaceuticals, Inc.NCT01659658Written as Lenalidomide
Showing 20 of 22.
What changed recently
From the registry's own updates since Oct 17, 2026.
Started recruiting2
Results posted1
Newly registered4
- Lenalidomide and Cosibelimab for the Treatment of Relapsed/Refractory Mycosis Fungoides or Sézary SyndromeNov 9, 2026NCT07926893
- Prophylactic Strategies for Mitigating Central Nervous System Relapse in Diffuse Large B-Cell LymphomaNov 4, 2026NCT07917624
- Zilovertamab Vedotin and Lenalidomide (ZiVLen) Therapy for Relapsed/Refractory Peripheral T-Cell LymphomaNov 3, 2026NCT07913594
- Chidamide, Lenalidomide, and Rituximab in Newly Diagnosed Elderly/unFit DE-DLBCLOct 20, 2026NCT07884708
Codes
What other systems call Lenalidomide · ClinicalTrials.gg INT006682
- MeSH (NLM) D000077269LenalidomideConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) F0P408N6V4LENALIDOMIDEConfirmed FDA, NLM, Wikidata
- RxNorm 342369Confirmed FDA, Wikidata
- Wikidata Q425681(RS)-lenalidomideConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C2668LenalidomideOne source FDA
- DrugBank DB00480One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000077269 | Lenalidomide | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | F0P408N6V4 | LENALIDOMIDE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 342369 | — | Confirmed FDA, Wikidata |
| Wikidata | Q425681 | (RS)-lenalidomide | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C2668 | Lenalidomide | One source FDA |
| DrugBank | DB00480 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.